|
1
|
Schwanhäusser B, Busse D, Li N, Dittmar G,
Schuchhardt J, Wolf J, Chen W and Selbach M: Global quantification
of mammalian gene expression control. Nature. 473:337–342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kechavarzi B and Janga SC: Dissecting the
expression landscape of RNA-binding proteins in human cancers.
Genome Biol. 15:R142014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wurth L and Gebauer F: RNA-binding
proteins, multifaceted translational regulators in cancer. Biochim
Biophys Acta. 1849:881–886. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdelmohsen K and Gorospe M:
Posttranscriptional regulation of cancer traits by HuR. Wiley
Interdiscip Rev RNA. 1:214–229. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wurth L: Versatility of RNA-binding
proteins in cancer. Comp Funct Genomics. 2012:1785252012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang J, Guo Y, Chu H, Guan Y, Bi J and
Wang B: Multiple functions of the RNA-binding protein HuR in cancer
progression, treatment responses and prognosis. Int J Mol Sci.
14:10015–10041. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Govindaraju S and Lee BS: Adaptive and
maladaptive expression of the mRNA regulatory protein HuR. World J
Biol Chem. 4:111–118. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baldan F, Mio C, Allegri L, Conzatti K,
Toffoletto B, Puppin C, Radovic S, Vascotto C, Russo D, Di Loreto C
and Damante G: Identification of tumorigenesis-related mRNAs
associated with RNA-binding protein HuR in thyroid cancer cells.
Oncotarget. 7:63388–63407. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pellegriti G, Frasca F, Regalbuto C,
Squatrito S and Vigneri R: Worldwide increasing incidence of
thyroid cancer: Update on epidemiology and risk factors. J Cancer
Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lebastchi AH and Callender GG: Thyroid
cancer. Curr Probl Cancer. 38:48–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O'Neill JP and Shaha AR: Anaplastic
thyroid cancer. Oral Oncol. 49:702–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chaitanya GV, Alexander JS and Babu PP:
PARP-1 cleavage fragments: Signatures of cell-death proteases in
neurodegeneration. Cell Commun Signal. 8:312010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ungerstedt JS, Sowa Y, Xu WS, Shao Y,
Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA:
Role of thioredoxin in the response of normal and transformed cells
to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 102:pp.
673–678. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baldan F, Mio C, Allegri L, Puppin C,
Russo D, Filetti S and Damante G: Synergy between HDAC and PARP
inhibitors on proliferation of a human anaplastic thyroid
cancer-derived cell line. Int J Endocrinol. 2015:9783712015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Ouyang W, Li J, Zhang D, Yu Y,
Wang Y, Li X and Huang C: Suberoylanilide hydroxamic acid (SAHA)
inhibits EGF-induced cell transformation via reduction of cyclin D1
mRNA stability. Toxicol Appl Pharmacol. 263:218–224. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kang M, Ryu B, Lee M, Han J, Lee JH, Ha
TK, Byun DS, Chae KS, Lee BH, Chun HS, et al: NF-kappaB activates
transcription of the RNA-binding factor HuR, via PI3K-AKT
signaling, to promote gastric tumorigenesis. Gastroenterology.
135:2030–2042.e1-3. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gilmore TD: Introduction to NF-kappaB:
Players, pathways, perspectives. Oncogene. 25:6680–6684. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Perkins ND: Integrating cell-signalling
pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol.
8:49–62. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Srikantan S and Gorospe M: HuR function in
disease. Front Biosci (Landmark Ed). 17:189–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blaxall BC, Dwyer-Nield LD, Bauer AK,
Bohlmeyer TJ, Malkinson AM and Port JD: Differential expression and
localization of the mRNA binding proteins, AU-rich element mRNA
binding protein (AUF1) and Hu antigen R (HuR), in neoplastic lung
tissue. Mol Carcinog. 28:76–83. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mann BS, Johnson JR, Cohen MH, Justice R
and Pazdur R: FDA approval summary: Vorinostat for treatment of
advanced primary cutaneous T-cell lymphoma. Oncologist.
12:1247–1252. 2007. View Article : Google Scholar : PubMed/NCBI
|
